ALB and esophageal squamous cell carcinoma: In conclusion, this study preliminarily confirmed that the albumin-binding paclitaxel combined with nedaplatin regimen has good clinical effect and tolerable toxicity in patients with operable ESCC, and is one of the alternative regiments for neoadjuvant therapy of ESCC patients.